Trade Names:Nplate- Injection, lyophilized 250 mcg- Injection, lyophilized 500 mcg
Increases platelet production by binding and activation of the thrombopoietin (TPO) receptor.
C max is 7 to 50 h postdose (median, 14 h).
Serum concentration does not correlate with the dose.
Elimination half-life ranges from 1 to 34 days (median, 3.5 days). Elimination is dependent in part on TPO receptors on platelets.
Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Romiplostim may only be prescribed by health care providers enrolled in the Network of Experts Understanding and Supporting (NEXUS) program and must be administered by prescribers or health care providers under their direction. This program provides educational materials and a mechanism for proper use of romiplostim.Adults
Subcutaneous Start with 1 mcg/kg based on actual body weight. Adjust the dose weekly by increments of 1 mcg/kg until the platelet count is at least 50 × 10 9 /L as needed to reduce the risk of bleeding (max, 10 mcg/kg/week). If the platelet count is less 50 × 10 9 /L, increase the dose by 1 mcg/kg. If the platelet count is more than 200 × 10 9 /L for 2 consecutive weeks, reduce the dose by 1 mcg/kg. If the platelet count is more than 400 × 10 9 /L, do not administer. Continue to assess the platelet count weekly. After the platelet count has fallen to less than 200 × 10 9 /L, resume at a dose reduced by 1 mcg/kg. Discontinue romiplostim if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 wk of therapy at the max dose of 10 mcg/kg.
Store in the refrigerator between 36° and 46°F. Do not freeze. Protect from light. Reconstituted romiplostim can be stored at 77°F or refrigerated between 36° and 46°F for up to 24 h prior to administration. Protect from light.
None well documented.
None well documented.
Dizziness (17%); insomnia (16%); paresthesia (6%).
Abdominal pain (11%); dyspepsia (7%).
Arthralgia (26%); myalgia (14%); shoulder pain (8%).
Pain in extremity (13%); antibody development (10%); development of binding antibody to endogenous TPO (5%).
Monitor CBCs, including platelet counts and peripheral blood smears, prior to initiation of treatment and throughout therapy. Monitor CBCs, including platelet counts, for at least 2 wk following discontinuation of treatment. Obtain CBCs, including platelet counts and peripheral blood smears, weekly during the dose adjustment phase and then monthly following establishment of a stable dose.
Category C .
Safety and efficacy not established.
Use with caution, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.
No clinical studies have been conducted in patients with renal function impairment; use with caution.
No clinical studies have been conducted in patients with hepatic function impairment; use with caution.
Risk for development or progression of reticulum fiber disposition within the bone marrow may be increased by romiplostim.
Failure or loss of a platelet response with romiplostim should prompt a search for causative factors, including neutralizing antibodies to romiplostim or bone marrow fibrosis.
Stimulation of the TPO receptor on the surface of hematopoietic cells by romiplostim may increase the risk for hematologic malignancies.
Discontinuation of romiplostim may result in thrombocytopenia that is of greater severity than was present prior to therapy, which may increase the risk of bleeding.
May result from excessive increases in platelet counts.
Platelet counts may increase excessively and result in thrombotic/thromboembolic complications.
Copyright © 2009 Wolters Kluwer Health.